Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 20,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $98.92, for a total transaction of $1,978,400.00. Following the sale, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $19,221,046.28. The trade was a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, July 6th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $122.27, for a total transaction of $2,445,400.00.
• On Monday, June 1st, Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00.

Mirum Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ MIRM opened at $98.23 on Wednesday. The company has a 50 day simple moving average of $110.50 and a 200-day simple moving average of $101.94. The company has a market capitalization of $6.38 billion, a P/E ratio of -6.75 and a beta of 0.52. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. Mirum Pharmaceuticals, Inc. has a 1 year low of $63.23 and a 1 year high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company’s revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.12) earnings per share. On average, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.24 earnings per share for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $30,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $32,000. CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $32,000. Quantbot Technologies LP acquired a new position in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $33,000. Finally, Comerica Bank increased its stake in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the period.

Wall Street Analysts Forecast Growth

MIRM has been the topic of several research analyst reports. Evercore restated an “outperform” rating and issued a $138.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 6th. TD Cowen dropped their price target on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. JPMorgan Chase & Co. boosted their price target on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Finally, Robert W. Baird set a $123.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.33.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.